Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Genitourinary 8Thoracic 5Breast 5Sarcoma 3Plasma cell 3Other hematologic neoplasm 3CNS 3NET 2Myeloid 2Lymphoid 2Gynecologic 2Endocrine 2Dermatologic 1

Conditions

Neuroendocrine Tumors 143Gastro-enteropancreatic neuroendocrine tumor 29Carcinoma, Neuroendocrine 18Neoplasms 15Breast Neoplasms 13Adenoma, Islet Cell 13Prostatic Neoplasms 11Carcinoma, Hepatocellular 11Carcinoid Tumor 11Stomach Neoplasms 10Pheochromocytoma 10Pancreatic Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Paraganglioma 9Thyroid Neoplasms 8Neoplasm Metastasis 8Lung Neoplasms 8Cholangiocarcinoma 8Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Melanoma 7Esophageal Neoplasms 7Anus Neoplasms 7Rectal Neoplasms 6Mesothelioma 6Colonic Neoplasms 6Carcinoma 6Brain Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease Progression × NET × 1 year × Clear all
NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

NCT02270567 2025-11-13

RegisterNET

Wren Laboratories LLC

Enrolling by invitation
400 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡